SARS-CoV-2 Antiviral Therapy

  title={SARS-CoV-2 Antiviral Therapy},
  author={Kaiming Tao and Philip L. Tzou and Janin Nouhin and Hector F. Bonilla and Prasanna Jagannathan and Robert W. Shafer},
  journal={Clinical Microbiology Reviews},
The development of effective antiviral therapy for COVID-19 is critical for those awaiting vaccination, as well as for those who do not respond robustly to vaccination. This review summarizes 1 year of progress in the race to develop antiviral therapies for COVID-19, including research spanning preclinical and clinical drug development efforts, with an emphasis on antiviral compounds that are in clinical development or that are high priorities for clinical development. SUMMARY The development… Expand
2 Citations
Antivirals for Coexistence with COVID-19: Brief Review for General Physicians
  • Jin-Hong Yoo
  • Medicine
  • Journal of Korean medical science
  • 2021
Although the severe acute respiratory syndrome coronavirus 2 will not be completely eradicated, if the use of antiviral drugs is established, the COVID-19 pandemic will end through coexistence with the virus. Expand
COVID-19 Pneumonia in Vaccinated Population: A Six Clinical and Radiological Case Series
It is suggested that in fully vaccinated people, caution should be preserved, and the use of masks and social distancing should be continued in all closed environments to better understand how various factors can influence vaccine immunogenicity as the presence of virus mutations, age factors, andThe presence of an immunocompromised state. Expand


Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
A panel of 48 FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS -CoV-2 infection, and a total of 24 drugs which exhibited antiviral efficacy were found. Expand
Neutralizing monoclonal antibodies for treatment of COVID-19
The precedent for passive immunization and lessons learned from using antibody therapies for viral infections such as respiratory syncytial virus, Ebola virus and SARS-CoV infections are reviewed and a need to understand factors such as the kinetics of viral load and its correlation with clinical outcomes is understood. Expand
Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
All antiviral drugs tested marginally reduced the overall clinical scores of infected ferrets but did not significantly affect in vivo virus titers. Expand
Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2
Five of the newly identified drugs had a safety index (cytotoxic/effective concentration) of >600, indicating wide therapeutic window compared to hydroxychloroquine which had safety index of 22 in similar experiments, and Mechanistically, five of the effective compounds were found to block SARS-CoV-2 S protein-mediated cell fusion. Expand
SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model
32 new bicycloproline-containing Mpro inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals are designed and synthesized and display excellent antiviral activity both in vitro and in a transgenic mouse model. Expand
Lack of Antiviral Activity of Darunavir against SARS-CoV-2
The data do not support the use of DRV for treatment of COVID-19 and the in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. Expand
REGEN-COV protects against viral escape in preclinical and human studies
This study demonstrates that a combination of non-competing antibodies, REGEN-COV, not only provides full coverage against current variants of concern/interest but also protects against emergence of new such variants and their potential seeding into the population in a clinical setting. Expand
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
The pharmacokinetic characteristics of favipiravir and possible drug–drug interactions from the view of drug metabolism are summarized in the hope this will be helpful for the design of clinical trials for favipIRavir in COVID‐2019. Expand
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Two peptidomimetic aldehydes were designed, synthesized, and evaluated as antiviral drug candidates, and both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity. Expand
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
The results indicate that plitidepsin is a promising therapeutic candidate for COVID-19, and in cells, the drug is substantially more potent than remdesivir against SARS-CoV-2, with limited cellular toxicity. Expand